These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32295435)

  • 1. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
    Safa H; Bhosale P; Weissferdt A; Oliva ICG
    Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
    Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
    Baba T; Sakai F; Kato T; Kusumoto M; Kenmotsu H; Sugiura H; Tominaga J; Oikado K; Sata M; Endo M; Yanagawa N; Sasaki S; Iwasawa T; Saito Y; Fujiwara Y; Ohe Y; Yamazaki N; Sakamoto T; Koshiba T; Kuwano K
    Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
    Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
    Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma.
    Cǎlugǎreanu A; Rompteaux P; Bohelay G; Goldfarb L; Barrau V; Cucherousset N; Heidelberger V; Nault JC; Ziol M; Caux F; Maubec E
    Immunotherapy; 2019 Aug; 11(12):1005-1013. PubMed ID: 31304833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Related Pneumonitis.
    Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
    Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
    de Jong C; Peters BJM; Schramel FMNH
    Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
    Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
    South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case of desmoplastic melanoma with lung metastasis maintaining complete response after cessation of nivolumab.
    Murayama A; Itoh M; Ito K; Tanito K; Ishida K; Nobeyama Y; Nakagawa H
    J Dermatol; 2017 Mar; 44(3):e17-e18. PubMed ID: 27461747
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report of nivolumab-related pneumonitis.
    Tada K; Kurihara Y; Myojo T; Kojima F; Ishikawa Y; Yoshiyasu N; Morimoto M; Ito R; Koyamada R; Yamashita T; Bando T; Mori S; Heike Y
    Immunotherapy; 2017 Mar; 9(4):313-318. PubMed ID: 28303763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
    Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 18. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 19. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.